New immune cell therapy targets Hard-to-Treat cancers

NCT ID NCT07474168

Ongoing Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recognize and attack cancer cells while also resisting tumor-suppressing signals. The study aims to check safety and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TCR-T cells targeting KRAS G12V mutation
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific KRAS mutation and no other standard treatments.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants, so results may not apply to everyone. The therapy is experimental and may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR

Contacts and locations

Locations

The First Affiliated Hospital of Zhejiang University school of Medicine

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.